Literature DB >> 12069910

Epidemiology of opportunistic invasive mycoses.

B J Kullberg1, A M L Oude Lashof.   

Abstract

Invasive aspergillosis and disseminated candidiasis are the two major manifestations of opportunistic invasive mycoses. Their incidence has risen considerably during the past decades, due to more intensive anticancer chemotherapy, organ transplantations, intensive care, and aggressive surgical interventions. Especially bone marrow transplant recipients are at risk for developing invasive aspergillosis. Whether the infection is acquired through contaminated water or through airborne spores is a matter of much debate. Candidemia and disseminated candidiasis commonly originate from the gastrointestinal tract. Abdominal surgery and mucosal damage due to anticancer chemotherapy are the majors factor through which gut colonization may lead to invasive disease. A shift in the epidemiology of disseminated candidiasis has been noted, with an increasing incidence of Candida glabrata, C. tropicalis and C. krusei strains.

Entities:  

Mesh:

Year:  2002        PMID: 12069910

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  52 in total

1.  Isolated bone marrow mycosis in a patient presenting with consumptive symptoms.

Authors:  A Zimpfer; P Piehler; G Kofler; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 2.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

Review 3.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

Review 4.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

5.  The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avenissian; Scott G Filler; Carter L Myers; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Salivary constituents and acidogenic microbial counts in coronary artery bypass graft patients from baseline to three-years after operation.

Authors:  Markku Qvarnström; Sok-Ja Janket; Pekka Nuutinen; Jussi Furuholm; Jukka H Meurman
Journal:  Clin Oral Investig       Date:  2007-03-31       Impact factor: 3.573

7.  Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.

Authors:  David Kadosh; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Nathan P Wiederhold; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  An Opaque Cell-Specific Expression Program of Secreted Proteases and Transporters Allows Cell-Type Cooperation in Candida albicans.

Authors:  Matthew B Lohse; Lucas R Brenes; Naomi Ziv; Michael B Winter; Charles S Craik; Alexander D Johnson
Journal:  Genetics       Date:  2020-08-24       Impact factor: 4.562

9.  Voriconazole salvage treatment of invasive candidiasis.

Authors:  L Ostrosky-Zeichner; A M L Oude Lashof; B J Kullberg; J H Rex
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-17       Impact factor: 3.267

10.  Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.

Authors:  Peter Kaskel; Silja Tuschy; Alexander Wagner; Christian Bannert; Oliver A Cornely; Axel Glasmacher; Hans-Peter Lipp; Andrew J Ullmann
Journal:  Ann Hematol       Date:  2007-10-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.